A peptide is a short chain of amino acids. Semaglutide, tirzepatide and BPC-157 are all built that way.
The four drugs on this page act on some of the same body systems as peptides on this site, but none of them is a peptide. All four are taken by mouth. They are ibutamoren (MK-677), macimorelin, anamorelin and orforglipron.
This matters when you read evidence. A drug that is not a peptide is a different kind of drug. Its safety record, its rules and its trials are its own. Peptide evidence does not carry over to it, and the reverse is also true. A result for one of these four says nothing about any peptide on this site.
This page is for information only. It gives no advice and no doses.
The four at a glance
| Substance | What it is | UK status on 14 November 2026 | Named on the WADA 2026 list (S2.2.4) |
|---|---|---|---|
| Ibutamoren (MK-677) | Non-peptide, small-molecule, oral growth hormone secretagogue | No UK licence found | Yes |
| Macimorelin | Not a peptide; it mimics one (a "peptidomimetic") | Licensed diagnostic test for adult growth hormone deficiency | Yes |
| Anamorelin | Oral drug that mimics ghrelin; not a peptide | No UK licence found | Yes |
| Orforglipron | Oral, non-peptide, small-molecule GLP-1 receptor agonist | Authorised by the MHRA on 10 August 2026; prescription-only | Not named |
Ibutamoren (MK-677)
UK status (checked 14 November 2026): no UK licence found. This is a record, not a recommendation, and it does not mean the substance is licensed or lawful to supply.
What it is
Ibutamoren is described as "a potent, long-acting, selective non-peptide growth hormone secretagogue that can be taken orally" and as a small molecule (Philip et al., 2022). A 2008 trial paper calls it "an oral ghrelin mimetic" (Nass et al., 2008). Ghrelin is the "hunger hormone". Ibutamoren acts like it and raises growth hormone (GH) and IGF-I.
What the main human evidence showed
The main human trial is from 2008. It was a 2-year, double-blind, placebo-controlled, modified-crossover trial in 65 healthy adults aged 60 to 81, with its primary endpoints at 1 year (Nass et al., 2008). We have not found a second trial that repeats it.
- GH and IGF-I rose to levels seen in healthy young adults.
- Fat-free mass fell 0.5 kg on placebo and rose 1.1 kg with ibutamoren (P < 0.001). Body weight rose 0.8 kg on placebo and 2.7 kg with ibutamoren (P = 0.003).
- There was no significant difference in abdominal visceral fat or total fat mass. Limb fat rose more with ibutamoren (P = 0.001).
- Fasting glucose rose by 0.3 mmol/L (P = 0.015), insulin sensitivity fell, and cortisol rose (P = 0.020).
- The main side effects were more appetite (which faded within a few months), mild leg swelling and muscle pain.
- The trial reported no serious adverse effects in 65 people over 2 years. That is too few people to rule out rarer harms. A 2026 review linked MK-677 to congestive heart failure and listed insulin resistance among the documented risks of the supplements it reviewed (see below).
More fat-free mass did not mean more strength or better function. The authors said the study was too small and too short to judge function. A rise in growth hormone or in body weight is a measurement. It is not a health benefit.
A 2026 scoping review in sports medicine looked at six peptides and MK-677. It found that human evidence is limited and that claimed benefits are not backed by current human trials. It linked MK-677 to congestive heart failure. It also listed insulin resistance among the documented risks of the supplements it reviewed, without tying that risk to MK-677 alone (Tewari et al., 2026). This was an abstract-level reading of a secondary source. The review lists MK-677 among "peptide supplements", which is the very mix-up this page corrects.
UK status
Ibutamoren is not on the MHRA Products active-substance index, checked on 14 November 2026. We found no UK licence. Absence from the index is a search result on that date, not a regulatory decision.
Sport
The WADA 2026 Prohibited List names ibutamoren under S2.2.4, growth hormone secretagogues.
Macimorelin
UK status (checked 14 November 2026): licensed in the UK as a diagnostic test only.
What it is
The UK product information calls macimorelin "an orally available peptidomimetic" (eMC SmPC). A peptidomimetic copies part of a peptide's shape but is not a chain of amino acids. So macimorelin is not a peptide; it mimics one.
It is a growth hormone secretagogue with ghrelin-like activity. It switches on the growth hormone secretagogue receptor (GHSR) in the pituitary and hypothalamus, which releases GH. A 2025 structural study found that it binds the same receptor pocket as anamorelin (Wang et al., 2025). That study used no patients.
Real use: a diagnostic test
Macimorelin is not a treatment. The UK product information gives it "for diagnostic use only", to help diagnose growth hormone deficiency in adults, under an experienced clinician (eMC SmPC).
The evidence we verified is a post hoc analysis of a randomised phase 3 study. It compared macimorelin with the insulin tolerance test (ITT) in adults aged 18 to 66 with a BMI under 37. At a cut-point of 5.1 ng/mL, sensitivity was 92%, specificity was 96% and agreement with the ITT was 87%. Age, BMI and sex did not meaningfully change performance (Garcia et al., 2021). The abstract gives no adverse-event data. This is a post hoc analysis, not the original trial report. We did not locate the original paper.
UK status
Macimorelin has a UK marketing authorisation. The MHRA substance index lists macimorelin (acetate) on 14 November 2026. The product information shows a UK product, macimorelin granules for oral suspension, with Atnahs Pharma UK Limited as the marketing authorisation holder. The indication is the diagnosis of growth hormone deficiency in adults (eMC SmPC).
Sport
The WADA 2026 Prohibited List names macimorelin under S2.2.4. A licensed diagnostic is still on the list.
Anamorelin
UK status (checked 14 November 2026): no UK licence found. Authorised in Japan. This is a record, not a recommendation, and it does not mean the drug is licensed or lawful to supply in the UK.
What it is
Anamorelin is an oral drug described as a "ghrelin mimetic" and a "ghrelin receptor agonist" (Garcia et al., 2013). A 2018 peer-reviewed review describes it as a non-peptide ghrelin analogue (Currow et al., 2018). It stimulates the ghrelin receptor, which raises appetite and GH. It binds the same pocket as macimorelin, and binds more strongly (Wang et al., 2025).
What the main human evidence showed
The main evidence is in cancer cachexia, the muscle and weight wasting seen in advanced cancer.
- ROMANA 1 and 2. These were two double-blind, placebo-controlled phase 3 trials in advanced non-small-cell lung cancer with cachexia. ROMANA 1 had 484 patients and ROMANA 2 had 495. Lean body mass rose by a median 0.99 kg versus a 0.47 kg loss on placebo in ROMANA 1, and rose 0.65 kg versus a 0.98 kg loss in ROMANA 2. Handgrip strength did not differ significantly in either trial (p = 0.15 and p = 0.65). Serious treatment-related adverse events (grade 3 to 4) did not differ between groups. The most common was high blood sugar, in under 1% of patients in ROMANA 1 and 1% in ROMANA 2. The authors concluded that anamorelin raised lean body mass but not handgrip strength (Temel et al., 2016).
- Gastric cancer cachexia, 2025. In an open-label randomised trial in Japan (203 people), lean body mass rose 0.99 kg versus 0.14 kg in controls. The difference was not statistically significant (p = 0.063). Five anamorelin patients had high blood sugar. The trial was funded by Ono Pharmaceutical (Yamamoto et al., 2025).
- Pilot study, 2013. A crossover study in 16 patients, small and short (Garcia et al., 2013).
In short, muscle mass moved a little and strength did not.
UK status
Anamorelin is not on the MHRA substance index, checked on 14 November 2026. We found no UK licence.
It is authorised in Japan. Ono Pharmaceutical reported authorisation for cancer cachexia in non-small-cell lung, gastric, pancreatic and colorectal cancer on 22 January 2021 (Ono Pharmaceutical press release). This is a company source.
Sport
The WADA 2026 Prohibited List names anamorelin under S2.2.4.
Orforglipron
UK status (checked 14 November 2026): authorised by the MHRA on 10 August 2026; prescription-only.
What it is
Orforglipron is an oral, non-peptide, small-molecule GLP-1 receptor agonist. Two 2026 papers use those words (Guo and Chen, 2026; Castro-Gamboa et al., 2026).
It matters because semaglutide and tirzepatide are peptides and are injected. Orforglipron acts on the same receptor, but it is a tablet and a different kind of molecule. It is not a peptide drug, even though it is a "GLP-1 drug". It switches on the GLP-1 receptor like the peptide GLP-1 drugs, but by mouth (Guo and Chen, 2026).
What the main human evidence showed
Two phase 3 trials were published in the New England Journal of Medicine in 2025. We read both from abstract records. Percentages are ranges across the treatment arms.
- ATTAIN-1 (obesity, no diabetes). 3,127 adults, double-blind, 72 weeks, with diet and activity advice. Weight loss at week 72 was about 7.5% to 11.2% across orforglipron arms, against about 2.1% on placebo. Stopping because of side effects happened in 5.3% to 10.3% of orforglipron groups against 2.7% on placebo. The most common side effects were mild-to-moderate gut symptoms (Wharton et al., 2025).
- ACHIEVE-1 (early type 2 diabetes). 559 adults, 40 weeks. HbA1c fell by about 1.2 to 1.5 points against about 0.4 on placebo. Weight fell about 4.5% to 7.6% against about 1.7%. There was no severe low blood sugar. Stopping because of side effects happened in 4.4% to 7.8% against 1.4% on placebo (Rosenstock et al., 2025).
Both trials were sponsored by Eli Lilly, the company that holds the UK authorisation.
- Pooled review, 2026. A systematic review of six randomised trials (6,022 people) found weight loss of about 4.5% to 14.7%. Gut effects were the most common side effect. This is a secondary source (Paredes Yacaman et al., 2026).
Weight loss is an average. Individual results varied. These were short trials in selected adults. The figures say nothing about long-term results.
UK status
The MHRA authorised orforglipron on 10 August 2026, to Eli Lilly. It is a prescription-only medicine. The authorised uses are weight loss and weight maintenance in adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related condition, alongside diet and activity; and improving blood-sugar control in type 2 diabetes that is not controlled well enough (gov.uk announcement; also reported by The Pharmaceutical Journal). Whether the NHS funds a medicine is a separate decision from its licence. The indication wording above is from the MHRA announcement, not the product information.
PeptGuru checked the MHRA Products register on 14 November 2026. Orforglipron hemicalcium is listed.
In the US, two 2026 papers report FDA approval for chronic weight management in April 2026 (Guo and Chen, 2026; Sheikh et al., 2026). We have not read the exact date from the FDA.
Sport
Orforglipron is not named on the WADA 2026 Prohibited List.
What to take from this page
- None of these four is a peptide. Do not carry a finding from them onto a peptide, or from a peptide onto them.
- Each has its own evidence. For ibutamoren and anamorelin, a gain in muscle or body weight did not come with a gain in strength.
- Two of the four hold UK authorisation: macimorelin, as a diagnostic test only, and orforglipron, as a prescription-only medicine for its authorised uses.
- No UK licence was found for ibutamoren or anamorelin. That is a search result on one date. It does not mean either is licensed or lawful to supply, and this page does not recommend any of the four.
- Three are named in the WADA 2026 list under S2.2.4. Orforglipron is not.
- Absence from the MHRA index on one date is a search result, not a regulatory decision.
See also our pages on semaglutide and tirzepatide, which are peptide GLP-1 drugs.